Anthony S. Chilton
Plus aucun poste en cours
Profil
Anthony S.
Chilton served as President, Chief Executive Officer & Director at Inotiv, Inc. from 2011 to 2012.
Prior to that, he was VP-Biopharmaceutical Development Division at Cardinal Health, Inc. and Vice President-PreClinical Development at Genmedica Therapeutics SL.
Chilton received his undergraduate degree from the University of East Anglia in 1981 and his doctorate from the University of Hertfordshire in 1993.
Anciens postes connus de Anthony S. Chilton
| Sociétés | Poste | Fin |
|---|---|---|
| INOTIV, INC. | President | 05/07/2012 |
| CARDINAL HEALTH, INC. | Corporate Officer/Principal | - |
Genmedica Therapeutics SL
 Genmedica Therapeutics SL BiotechnologyHealth Technology Genmedica Therapeutics SL engages in the research and development of new treatments for diabetes. Its has developed novel NCE-generating platform to generate dual action, small molecules that act against oxidative stress and inflammation, two specific pathways known to be critical in the root causes of the disease. The company was founded by Alec Humayun Mian and Luc Marti Clauzel on June 21, 2004 and is headquartered in Barcelona, Spain. | Corporate Officer/Principal | - |
Formation de Anthony S. Chilton
| University of East Anglia | Undergraduate Degree |
| University of Hertfordshire | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| INOTIV, INC. | Commercial Services |
| CARDINAL HEALTH, INC. | Distribution Services |
| Entreprise privées | 1 |
|---|---|
Genmedica Therapeutics SL
Genmedica Therapeutics SL BiotechnologyHealth Technology Genmedica Therapeutics SL engages in the research and development of new treatments for diabetes. Its has developed novel NCE-generating platform to generate dual action, small molecules that act against oxidative stress and inflammation, two specific pathways known to be critical in the root causes of the disease. The company was founded by Alec Humayun Mian and Luc Marti Clauzel on June 21, 2004 and is headquartered in Barcelona, Spain. | Health Technology |
